Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Sequential Capecitabine Plus Oxaliplatin (XELOX) Followed by Docetaxel Plus Capecitabine (TX) in Patients With Unresectable Gastric

NCT01331928 is registered in ClinicalTrials.gov with Taipei Veterans General Hospital, Taiwan as lead sponsor.

NCT NCT01331928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01331928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Sequential Capecitabine Plus Oxaliplatin (XELOX) Followed by Docetaxel Plus Capecitabine (TX) in Patients With Unresectable Gastric
Lead sponsor
Taipei Veterans General Hospital, Taiwan
Phase
Phase 2
Overall status
Unknown status
Start date
January 31, 2011
Completion date
Not reported
Enrollment
51 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer